Increases Lipoprotein Lipase Activity with Resulting Elevation of High Density Lipoprotein Cholesterol, and Long-term Administra tion Inhibits Atherogenesis in the Coronary Arteries of Rats

Kazuhiko Tsutsumi, et al., “The Novel Compound NO-1886 Increases Lipoprotein Lipase Activity with Resulting Elevation of High Density Lipoprotein Cholesterol, and Long-term Administra tion Inhibits Atherogenesis in the Coronary Arteries of Rats with Experimental Atherosclerosis”. J. Clin. Invest., vol. 92, pp. 411-417 (Jul 1993). Kazuhiko Tsutsumi, et al., “Suppression of Hyperlipidemia-Associ ated Cataracts in Diabetic Rats with the Lipoprotein Lipase Activator NO-1886, Biol. Pharm. Bull., vol. 19, No. 12, pp. 1570-1573 (1996). Ikuo Kawamura, et al., “Effect of Lipoprotein Lipase Activators Bezafibrate and NO-1885, on B16 Melanoma-Induced Cachexia in Mice'. Anticancer Research, vol. 19, pp. 4099-4104 (1999). Kaori Nakayama, et al., “Effect of the Lipoprotein Lipase Activator NO-1866 on Adriamycin-Induced Nephrotic Syndrome in Rats'. Metabolism, vol. 49, No. 5, pp. 588-593 (May 2000). Kazuhiko Tsutsumi, et al., "Correction of Hypertriglyceridemia with Low High-Density Lipoprotein Cholesterol by the Novel Compound NO-1886, a Lipoprotein Lipase-Promoting Agent, in STZ-Induced Diabetic Rats', Diabetes, vol. 44, pp. 414-417 (Apr. 1995). M. Kusunoki, et al., “The lipoprotein lipase activator, NO-1886, Suppresses fat accumulation and insulin resistance in rats fed a high fat diet”. Diabetologia, vol.43, pp. 875-880 (2000). Supplementary European Search Report dated Aug. 16, 2012 in EP 10 73 8531.